• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

SALMETEROL Drug Record

  • Summary
  • Interactions
  • Claims
  • SALMETEROL chembl:CHEMBL1263 Approved

    Alternate Names:

    SEREVENT
    SALMETEROL
    BEGLAN
    GR-33343-X
    SN408D
    NEOVENT
    GR-33343X
    SALMATEROL
    VERTINE
    SOLTEL
    GR 33343X
    SEREVENT®
    SALMETEROLUM
    chembl:CHEMBL1263
    pubchem.compound:5152
    chemidplus:89365-50-4
    drugbank:00938
    rxcui:36117

    Drug Info:

    Drug Class bronchodilator agents
    Year of Approval 1994
    FDA Approval approved
    Drug Class Small Molecule
    Drug Indications bronchodilator
    (2 More Sources)

    Publications:

    Hoffmann et al., 2004, Comparative pharmacology of human beta-adrenergic receptor subtypes--characterization of stably transfected receptors in CHO cells., Naunyn Schmiedebergs Arch. Pharmacol.
    Brogden et al., Salmeterol xinafoate: a review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease., Allergol Immunopathol (Madr)
    Finney et al., 2001, Chronic systemic administration of salmeterol to rats promotes pulmonary beta(2)-adrenoceptor desensitization and down-regulation of G(s alpha)., Br. J. Pharmacol.
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Rong et al., 1999, Probing the salmeterol binding site on the beta 2-adrenergic receptor using a novel photoaffinity ligand, [(125)I]iodoazidosalmeterol., Biochemistry
    Green et al., 2001, The Ile164 beta(2)-adrenoceptor polymorphism alters salmeterol exosite binding and conventional agonist coupling to G(s)., Eur. J. Pharmacol.
    Meliton et al., 2003, Blockade of LTC4 synthesis caused by additive inhibition of gIV-PLA2 phosphorylation: Effect of salmeterol and PDE4 inhibition in human eosinophils., J. Allergy Clin. Immunol.
    Zuurhout MJ et al., 2013, Arg16 ADRB2 genotype increases the risk of asthma exacerbation in children with a reported use of long-acting β2-agonists: results of the PACMAN cohort., Pharmacogenomics
    Lipworth BJ et al., 2013, Tailored second-line therapy in asthmatic children with the Arg(16) genotype., Clin Sci (Lond)
    Wechsler ME et al., 2009, Effect of beta2-adrenergic receptor polymorphism on response to longacting beta2 agonist in asthma (LARGE trial): a genotype-stratified, randomised, placebo-controlled, crossover trial., Lancet
    Basu K et al., 2009, Adrenergic beta(2)-receptor genotype predisposes to exacerbations in steroid-treated asthmatic patients taking frequent albuterol or salmeterol., J Allergy Clin Immunol
    Bleecker ER et al., 2007, Effect of ADRB2 polymorphisms on response to longacting beta2-agonist therapy: a pharmacogenetic analysis of two randomised studies., Lancet
    Israel E et al., 2004, Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial., Lancet
    Cazzola M et al., 2002, Clinical pharmacokinetics of salmeterol., Clin Pharmacokinet
    Zanger UM et al., 2008, Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation., Anal Bioanal Chem
  • SALMETEROL   ADRB2

    Interaction Score: 2.05

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Trial Name Advair/Seretide/Adoair
    Novel drug target Established target
    Trial Name Serevent

    PMIDs:
    1359777 11250877 11752352 10471277 11516429 12897749 24279851 23126384 19932356 19800676 18156033 15500895 11825095


    Sources:
    TdgClinicalTrial TEND PharmGKB TTD

  • SALMETEROL   ADRB1

    Interaction Score: 0.37

    Interaction Types & Directionality:
    inverse agonist (inhibitory)

    Interaction Info:

    PMIDs:
    14730417


    Sources:
    DTC

  • SALMETEROL   CYP3A5

    Interaction Score: 0.3

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18695978


    Sources:
    PharmGKB

  • SALMETEROL   AR

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • TEND: SALMETEROL

    • Version: 01-August-2011

    Alternate Names:
    SALMETEROL Primary Drug Name

    Drug Info:
    Year of Approval 1994
    Drug Class bronchodilator agents

    Publications:

  • TdgClinicalTrial: SALMETEROL

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications bronchodilator
    Drug Class Small Molecule
    FDA Approval approved

    Publications:

  • PharmGKB: salmeterol

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Zanger UM et al., 2008, Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation., Anal Bioanal Chem
    Lipworth BJ et al., 2013, Tailored second-line therapy in asthmatic children with the Arg(16) genotype., Clin Sci (Lond)
    Israel E et al., 2004, Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial., Lancet

  • DTC: SALMETEROL

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL1263 ChEMBL Drug ID

    Drug Info:

    Publications:

  • TTD: Salmeterol

    • Version: 2020.06.01

    Alternate Names:
    D0L5YV TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL1263

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21